Skip to main content
Top
Published in: Virology Journal 1/2010

Open Access 01-12-2010 | Research

A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats

Authors: Myra N Widjojoatmodjo, Jolande Boes, Marleen van Bers, Yvonne van Remmerden, Paul JM Roholl, Willem Luytjes

Published in: Virology Journal | Issue 1/2010

Login to get access

Abstract

Background

Respiratory syncytial virus (RSV) is a primary cause of serious lower respiratory tract illness for which there is still no safe and effective vaccine available. Using reverse genetics, recombinant (r)RSV and an rRSV lacking the G gene (ΔG) were constructed based on a clinical RSV isolate (strain 98-25147-X).

Results

Growth of both recombinant viruses was equivalent to that of wild type virus in Vero cells, but was reduced in human epithelial cells like Hep-2. Replication in cotton rat lungs could not be detected for ΔG, while rRSV was 100-fold attenuated compared to wild type virus. Upon single dose intranasal administration in cotton rats, both recombinant viruses developed high levels of neutralizing antibodies and conferred comparable long-lasting protection against RSV challenge; protection against replication in the lungs lasted at least 147 days and protection against pulmonary inflammation lasted at least 75 days.

Conclusion

Collectively, the data indicate that a single dose immunization with the highly attenuated ΔG as well as the attenuated rRSV conferred long term protection in the cotton rat against subsequent RSV challenge, without inducing vaccine enhanced pathology. Since ΔG is not likely to revert to a less attenuated phenotype, we plan to evaluate this deletion mutant further and to investigate its potential as a vaccine candidate against RSV infection.
Appendix
Available only for authorised users
Literature
1.
go back to reference Staat MA: Respiratory syncytial virus infections in children. Semin Respir Infect. 2002, 17: 15-20. 10.1053/srin.2002.31688.PubMedCrossRef Staat MA: Respiratory syncytial virus infections in children. Semin Respir Infect. 2002, 17: 15-20. 10.1053/srin.2002.31688.PubMedCrossRef
2.
go back to reference Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ: Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999, 282: 1440-1446. 10.1001/jama.282.15.1440.PubMedCrossRef Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ: Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999, 282: 1440-1446. 10.1001/jama.282.15.1440.PubMedCrossRef
3.
go back to reference Castilow EM, Varga SM: Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination. Future Virol. 2008, 3: 445-454. 10.2217/17460794.3.5.445.PubMedPubMedCentralCrossRef Castilow EM, Varga SM: Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination. Future Virol. 2008, 3: 445-454. 10.2217/17460794.3.5.445.PubMedPubMedCentralCrossRef
4.
go back to reference Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, Diaz L, Trento A, Chang HY, Mitzner W, Ravetch J, Melero JA, Irusta PM, Polack FP: Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med. 2009, 15: 34-41. 10.1038/nm.1894.PubMedPubMedCentralCrossRef Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, Diaz L, Trento A, Chang HY, Mitzner W, Ravetch J, Melero JA, Irusta PM, Polack FP: Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med. 2009, 15: 34-41. 10.1038/nm.1894.PubMedPubMedCentralCrossRef
6.
go back to reference Schickli JH, Dubovsky F, Tang RS: Challenges in developing a pediatric RSV vaccine. Hum Vaccin. 2009, 5: 582-591.PubMedCrossRef Schickli JH, Dubovsky F, Tang RS: Challenges in developing a pediatric RSV vaccine. Hum Vaccin. 2009, 5: 582-591.PubMedCrossRef
7.
go back to reference Wright PF, Karron RA, Belshe RB, Shi JR, Randolph VB, Collins PL, O'Shea AF, Gruber WC, Murphy BR: The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine. 2007, 25: 7372-7378. 10.1016/j.vaccine.2007.08.014.PubMedPubMedCentralCrossRef Wright PF, Karron RA, Belshe RB, Shi JR, Randolph VB, Collins PL, O'Shea AF, Gruber WC, Murphy BR: The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine. 2007, 25: 7372-7378. 10.1016/j.vaccine.2007.08.014.PubMedPubMedCentralCrossRef
8.
go back to reference Collins PL, Murphy BR: New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proc Am Thorac Soc. 2005, 2: 166-173. 10.1513/pats.200501-011AW.PubMedPubMedCentralCrossRef Collins PL, Murphy BR: New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proc Am Thorac Soc. 2005, 2: 166-173. 10.1513/pats.200501-011AW.PubMedPubMedCentralCrossRef
9.
go back to reference Hendricks DA, McIntosh K, Patterson JL: Further characterization of the soluble form of the G glycoprotein of respiratory syncytial virus. J Virol. 1988, 62: 2228-2233.PubMedPubMedCentral Hendricks DA, McIntosh K, Patterson JL: Further characterization of the soluble form of the G glycoprotein of respiratory syncytial virus. J Virol. 1988, 62: 2228-2233.PubMedPubMedCentral
10.
go back to reference Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology. 2001, 289: 283-296. 10.1006/viro.2001.1138.PubMedCrossRef Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology. 2001, 289: 283-296. 10.1006/viro.2001.1138.PubMedCrossRef
11.
go back to reference Johnson PR, Spriggs MK, Olmsted RA, Collins PL: The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci USA. 1987, 84: 5625-5629. 10.1073/pnas.84.16.5625.PubMedPubMedCentralCrossRef Johnson PR, Spriggs MK, Olmsted RA, Collins PL: The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci USA. 1987, 84: 5625-5629. 10.1073/pnas.84.16.5625.PubMedPubMedCentralCrossRef
12.
go back to reference Karron RA, Wright PF, Crowe JE, Clements-Mann ML, Thompson J, Makhene M, Casey R, Murphy BR: Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis. 1997, 176: 1428-1436. 10.1086/514138.PubMedCrossRef Karron RA, Wright PF, Crowe JE, Clements-Mann ML, Thompson J, Makhene M, Casey R, Murphy BR: Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis. 1997, 176: 1428-1436. 10.1086/514138.PubMedCrossRef
13.
go back to reference Schmidt U, Beyer J, Polster U, Gershwin LJ, Buchholz UJ: Mucosal immunization with live recombinant bovine respiratory syncytial virus (BRSV) and recombinant BRSV lacking the envelope glycoprotein G protects against challenge with wild-type BRSV. J Virol. 2002, 76: 12355-12359. 10.1128/JVI.76.23.12355-12359.2002.PubMedPubMedCentralCrossRef Schmidt U, Beyer J, Polster U, Gershwin LJ, Buchholz UJ: Mucosal immunization with live recombinant bovine respiratory syncytial virus (BRSV) and recombinant BRSV lacking the envelope glycoprotein G protects against challenge with wild-type BRSV. J Virol. 2002, 76: 12355-12359. 10.1128/JVI.76.23.12355-12359.2002.PubMedPubMedCentralCrossRef
14.
go back to reference Elliott MB, Pryharski KS, Yu Q, Boutilier LA, Campeol N, Melville K, Laughlin TS, Gupta CK, Lerch RA, Randolph VB, LaPierre NA, Dack KM, Hancock GE: Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein. J Virol. 2004, 78: 8446-8454. 10.1128/JVI.78.16.8446-8454.2004.PubMedPubMedCentralCrossRef Elliott MB, Pryharski KS, Yu Q, Boutilier LA, Campeol N, Melville K, Laughlin TS, Gupta CK, Lerch RA, Randolph VB, LaPierre NA, Dack KM, Hancock GE: Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein. J Virol. 2004, 78: 8446-8454. 10.1128/JVI.78.16.8446-8454.2004.PubMedPubMedCentralCrossRef
15.
go back to reference Prince GA, Jenson AB, Hemming VG, Murphy BR, Walsh EE, Horswood RL, Chanock RM: Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J Virol. 1986, 57: 721-728.PubMedPubMedCentral Prince GA, Jenson AB, Hemming VG, Murphy BR, Walsh EE, Horswood RL, Chanock RM: Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J Virol. 1986, 57: 721-728.PubMedPubMedCentral
16.
go back to reference Prince GA, Prieels JP, Slaoui M, Porter DD: Pulmonary lesions in primary respiratory syncytial virus infection, reinfection, and vaccine-enhanced disease in the cotton rat (Sigmodon hispidus). Lab Invest. 1999, 79: 1385-1392.PubMed Prince GA, Prieels JP, Slaoui M, Porter DD: Pulmonary lesions in primary respiratory syncytial virus infection, reinfection, and vaccine-enhanced disease in the cotton rat (Sigmodon hispidus). Lab Invest. 1999, 79: 1385-1392.PubMed
17.
go back to reference Jin H, Clarke D, Zhou HZ, Cheng X, Coelingh K, Bryant M, Li S: Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV. Virology. 1998, 251: 206-214. 10.1006/viro.1998.9414.PubMedCrossRef Jin H, Clarke D, Zhou HZ, Cheng X, Coelingh K, Bryant M, Li S: Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV. Virology. 1998, 251: 206-214. 10.1006/viro.1998.9414.PubMedCrossRef
18.
go back to reference Moudy RM, Sullender WM, Wertz GW: Variations in intergenic region sequences of Human respiratory syncytial virus clinical isolates: analysis of effects on transcriptional regulation. Virology. 2004, 327: 121-133. 10.1016/j.virol.2004.06.013.PubMedCrossRef Moudy RM, Sullender WM, Wertz GW: Variations in intergenic region sequences of Human respiratory syncytial virus clinical isolates: analysis of effects on transcriptional regulation. Virology. 2004, 327: 121-133. 10.1016/j.virol.2004.06.013.PubMedCrossRef
19.
go back to reference Karron RA, Buonagurio DA, Georgiu AF, Whitehead SS, Adamus JE, Clements-Mann ML, Harris DO, Randolph VB, Udem SA, Murphy BR, Sidhu MS: Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc Natl Acad Sci USA. 1997, 94: 13961-13966. 10.1073/pnas.94.25.13961.PubMedPubMedCentralCrossRef Karron RA, Buonagurio DA, Georgiu AF, Whitehead SS, Adamus JE, Clements-Mann ML, Harris DO, Randolph VB, Udem SA, Murphy BR, Sidhu MS: Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc Natl Acad Sci USA. 1997, 94: 13961-13966. 10.1073/pnas.94.25.13961.PubMedPubMedCentralCrossRef
20.
go back to reference Maher CF, Hussell T, Blair E, Ring CJ, Openshaw PJ: Recombinant respiratory syncytial virus lacking secreted glycoprotein G is attenuated, non-pathogenic but induces protective immunity. Microbes Infect. 2004, 6: 1049-1055. 10.1016/j.micinf.2004.07.001.PubMedCrossRef Maher CF, Hussell T, Blair E, Ring CJ, Openshaw PJ: Recombinant respiratory syncytial virus lacking secreted glycoprotein G is attenuated, non-pathogenic but induces protective immunity. Microbes Infect. 2004, 6: 1049-1055. 10.1016/j.micinf.2004.07.001.PubMedCrossRef
21.
go back to reference Arnold R, Konig B, Werchau H, Konig W: Respiratory syncytial virus deficient in soluble G protein induced an increased proinflammatory response in human lung epithelial cells. Virology. 2004, 330: 384-397. 10.1016/j.virol.2004.10.004.PubMedCrossRef Arnold R, Konig B, Werchau H, Konig W: Respiratory syncytial virus deficient in soluble G protein induced an increased proinflammatory response in human lung epithelial cells. Virology. 2004, 330: 384-397. 10.1016/j.virol.2004.10.004.PubMedCrossRef
22.
go back to reference Schwarze J, Schauer U: Enhanced virulence, airway inflammation and impaired lung function induced by respiratory syncytial virus deficient in secreted G protein. Thorax. 2004, 59: 517-521. 10.1136/thx.2003.017343.PubMedPubMedCentralCrossRef Schwarze J, Schauer U: Enhanced virulence, airway inflammation and impaired lung function induced by respiratory syncytial virus deficient in secreted G protein. Thorax. 2004, 59: 517-521. 10.1136/thx.2003.017343.PubMedPubMedCentralCrossRef
23.
go back to reference Biacchesi S, Skiadopoulos MH, Yang L, Lamirande EW, Tran KC, Murphy BR, Collins PL, Buchholz UJ: Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate. J Virol. 2004, 78: 12877-12887. 10.1128/JVI.78.23.12877-12887.2004.PubMedPubMedCentralCrossRef Biacchesi S, Skiadopoulos MH, Yang L, Lamirande EW, Tran KC, Murphy BR, Collins PL, Buchholz UJ: Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate. J Virol. 2004, 78: 12877-12887. 10.1128/JVI.78.23.12877-12887.2004.PubMedPubMedCentralCrossRef
24.
go back to reference Srikiatkhachorn A, Braciale TJ: Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J Exp Med. 1997, 186: 421-432. 10.1084/jem.186.3.421.PubMedPubMedCentralCrossRef Srikiatkhachorn A, Braciale TJ: Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J Exp Med. 1997, 186: 421-432. 10.1084/jem.186.3.421.PubMedPubMedCentralCrossRef
25.
go back to reference Openshaw PJ, Dean GS, Culley FJ: Links between respiratory syncytial virus bronchiolitis and childhood asthma: clinical and research approaches. Pediatr Infect Dis J. 2003, 22: S58-S64. 10.1097/00006454-200302001-00009.PubMed Openshaw PJ, Dean GS, Culley FJ: Links between respiratory syncytial virus bronchiolitis and childhood asthma: clinical and research approaches. Pediatr Infect Dis J. 2003, 22: S58-S64. 10.1097/00006454-200302001-00009.PubMed
26.
go back to reference Johnson TR, Teng MN, Collins PL, Graham BS: Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV. J Virol. 2004, 78: 6024-6032. 10.1128/JVI.78.11.6024-6032.2004.PubMedPubMedCentralCrossRef Johnson TR, Teng MN, Collins PL, Graham BS: Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV. J Virol. 2004, 78: 6024-6032. 10.1128/JVI.78.11.6024-6032.2004.PubMedPubMedCentralCrossRef
27.
go back to reference Gruenert DC, Basbaum CB, Welsh MJ, Li M, Finkbeiner WE, Nadel JA: Characterization of human tracheal epithelial cells transformed by an origin-defective simian virus 40. Proc Natl Acad Sci USA. 1988, 85: 5951-5955. 10.1073/pnas.85.16.5951.PubMedPubMedCentralCrossRef Gruenert DC, Basbaum CB, Welsh MJ, Li M, Finkbeiner WE, Nadel JA: Characterization of human tracheal epithelial cells transformed by an origin-defective simian virus 40. Proc Natl Acad Sci USA. 1988, 85: 5951-5955. 10.1073/pnas.85.16.5951.PubMedPubMedCentralCrossRef
28.
go back to reference Collins PL, Whitehead SS, Bukreyev A, Fearns R, Teng MN, Juhasz K: Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. Adv Virus Res. 1999, 54: 423-451. full_text.PubMedCrossRef Collins PL, Whitehead SS, Bukreyev A, Fearns R, Teng MN, Juhasz K: Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. Adv Virus Res. 1999, 54: 423-451. full_text.PubMedCrossRef
29.
go back to reference Collins PL, McIntosh K, Chanock RM: Respiratory syncytial virus. Fields Virology. Edited by: Fields BN, Knipe DN, Howley PM. 1996, Philadelphia: Lippincott-Raven Publishers, 1313-1351. Collins PL, McIntosh K, Chanock RM: Respiratory syncytial virus. Fields Virology. Edited by: Fields BN, Knipe DN, Howley PM. 1996, Philadelphia: Lippincott-Raven Publishers, 1313-1351.
Metadata
Title
A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats
Authors
Myra N Widjojoatmodjo
Jolande Boes
Marleen van Bers
Yvonne van Remmerden
Paul JM Roholl
Willem Luytjes
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2010
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-7-114

Other articles of this Issue 1/2010

Virology Journal 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.